Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP)

AURORA study designed to evaluate bitopertin as a potential disease-modifying treatment for adults with EPP in the United States.

Aurora study designed to assess changes in protoporphyrin IX levels, safety, tolerability, photosensitivity and other measures in a double-blind, placebo-controlled setting; SEE https://www.discmedicine.com/news/disc-medicine-initiates-aurora-a-phase-2-clinical-study-of-bitopertin-in-adults-with-erythropoietic-protoporphyria-epp/

Also see: https://clinicaltrials.gov/ct2/show/NCT05308472